Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Related records

Trials (15)

• A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
• A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors
• Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
• Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
• Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis
• Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
• Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
• Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
• Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps
• Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis
• Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
• Phase I Clinical Trial of TQB2825 Subcutaneous Injection in CD20-positive Hematological Malignancies
• To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
• TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
• Treatment of Recurrent/Metastatic Head and Neck Cancer